1. Home
  2. RCKT vs TCI Comparison

RCKT vs TCI Comparison

Compare RCKT & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCKT
  • TCI
  • Stock Information
  • Founded
  • RCKT 1999
  • TCI 1983
  • Country
  • RCKT United States
  • TCI United States
  • Employees
  • RCKT N/A
  • TCI N/A
  • Industry
  • RCKT Biotechnology: Pharmaceutical Preparations
  • TCI Real Estate
  • Sector
  • RCKT Health Care
  • TCI Finance
  • Exchange
  • RCKT Nasdaq
  • TCI Nasdaq
  • Market Cap
  • RCKT 328.6M
  • TCI 357.8M
  • IPO Year
  • RCKT N/A
  • TCI N/A
  • Fundamental
  • Price
  • RCKT $3.28
  • TCI $45.60
  • Analyst Decision
  • RCKT Buy
  • TCI
  • Analyst Count
  • RCKT 13
  • TCI 0
  • Target Price
  • RCKT $12.96
  • TCI N/A
  • AVG Volume (30 Days)
  • RCKT 6.0M
  • TCI 1.8K
  • Earning Date
  • RCKT 08-07-2025
  • TCI 08-07-2025
  • Dividend Yield
  • RCKT N/A
  • TCI N/A
  • EPS Growth
  • RCKT N/A
  • TCI 11.20
  • EPS
  • RCKT N/A
  • TCI 0.76
  • Revenue
  • RCKT N/A
  • TCI $47,730,000.00
  • Revenue This Year
  • RCKT N/A
  • TCI N/A
  • Revenue Next Year
  • RCKT $108.43
  • TCI N/A
  • P/E Ratio
  • RCKT N/A
  • TCI $61.66
  • Revenue Growth
  • RCKT N/A
  • TCI N/A
  • 52 Week Low
  • RCKT $2.19
  • TCI $25.50
  • 52 Week High
  • RCKT $22.01
  • TCI $48.00
  • Technical
  • Relative Strength Index (RSI)
  • RCKT 51.17
  • TCI 56.33
  • Support Level
  • RCKT $2.88
  • TCI $46.00
  • Resistance Level
  • RCKT $3.74
  • TCI $48.00
  • Average True Range (ATR)
  • RCKT 0.27
  • TCI 0.80
  • MACD
  • RCKT 0.02
  • TCI 0.05
  • Stochastic Oscillator
  • RCKT 35.43
  • TCI 67.90

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

Share on Social Networks: